Aberdeen Group plc Acquires 6,956 Shares of DaVita Inc. $DVA

Aberdeen Group plc boosted its holdings in DaVita Inc. (NYSE:DVA) by 16.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,209 shares of the company’s stock after acquiring an additional 6,956 shares during the quarter. Aberdeen Group plc’s holdings in DaVita were worth $7,010,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. National Pension Service increased its stake in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after buying an additional 84 shares during the last quarter. Y.D. More Investments Ltd purchased a new stake in DaVita in the 1st quarter valued at about $35,000. Ameritas Advisory Services LLC purchased a new stake in DaVita in the 2nd quarter valued at about $47,000. NewEdge Advisors LLC increased its stake in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after buying an additional 88 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in DaVita in the 1st quarter valued at about $83,000. Institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

DaVita Price Performance

Shares of NYSE:DVA opened at $125.18 on Friday. The firm has a fifty day moving average price of $132.56 and a two-hundred day moving average price of $138.60. DaVita Inc. has a one year low of $122.93 and a one year high of $179.60. The company has a market cap of $8.95 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 0.90 and a beta of 1.13.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the firm earned $2.00 EPS. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DVA shares. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Truist Financial set a $140.00 price target on shares of DaVita in a research note on Tuesday. Barclays decreased their price target on shares of DaVita from $160.00 to $149.00 and set an “equal weight” rating for the company in a research note on Thursday, October 9th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Wednesday, October 8th. Finally, Bank of America decreased their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research note on Wednesday, September 10th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $153.25.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.